IRs and HRs with 95% CIs of MDS/AML comparing NHL patients in the SLR subcohort to matched population comparators
| . | Patients, n . | Events, n . | Rate(per 10 000 person-years) . | HR(95% CI)* . | P interaction . |
|---|---|---|---|---|---|
| Comparators | 108 474 | 206 | 2.4 (2.1-2.7) | 1.00 (ref) | NA |
| All NHL combined | 21 695 | 131 | 10.7 (9.0-12.7) | 4.8 (3.9-6.0) | |
| Sex† | |||||
| Male | 12 072 | 76 | 11.4 (9.1-14.2) | 4.7 (3.5-6.3) | .750 |
| Female | 9 623 | 55 | 10.0 (7.7-13.0) | 5.0 (3.6-7.1) | |
| Age at diagnosis† | |||||
| <70 y | 10 770 | 81 | 10.1 (8.2-12.6) | 7.8 (5.6-10.7) | <.001 |
| ≥70 y | 10 925 | 50 | 11.9 (9.0-15.6) | 3.1 (2.3-4.3) | |
| Period of diagnosis† | |||||
| 2000-2004 | 6 600 | 51 | 10.8 (8.2-14.2) | 6.0 (4.2-8.6) | .321 |
| 2005-2009 | 7 313 | 45 | 10.2 (7.6-13.7) | 4.5 (3.1-6.5) | |
| 2010-2014 | 7 782 | 35 | 11.4 (8.2-15.8) | 4.0 (2.6-6.1) | |
| Lymphoma group† | |||||
| Low-grade NHL | 10 091 | 57 | 8.8 (6.8-11.3) | 4.1 (3.0-5.7) | .355 |
| High-grade NHL | 11 088 | 70 | 12.8 (10.1-16.2) | 5.6 (4.2-7.6) | |
| Other/unknown | 516 | 4 | 17.7 (6.6-47.1) | 6.2 (1.7-21.8) | |
| Lymphoma subtype† | |||||
| Diffuse large B cell | 8 144 | 46 | 11.0 (8.3-14.7) | 5.1 (3.5-7.5) | .657 |
| Follicular | 3 593 | 27 | 10.2 (7.0-14.8) | 5.4 (3.2-9.0) | |
| Mantel cell | 1 360 | 9 | 15.1 (7.9-29.1) | 4.9 (2.2-10.9) | |
| Marginal zone | 1 298 | 6 | 7.0 (3.2-15.6) | 3.0 (1.1-8.0) | |
| Burkitt | 227 | 2 | 15.0 (3.8-60.2) | 3.2 (0.6-16.5) | |
| T cell | 1 648 | 13 | 17.0 (9.9-29.2) | 8.5 (4.0-18.2) | |
| Other | 5 425 | 28 | 9.3 (6.4-13.4) | 4.1 (2.6-6.4) | |
| . | Patients, n . | Events, n . | Rate(per 10 000 person-years) . | HR(95% CI)* . | P interaction . |
|---|---|---|---|---|---|
| Comparators | 108 474 | 206 | 2.4 (2.1-2.7) | 1.00 (ref) | NA |
| All NHL combined | 21 695 | 131 | 10.7 (9.0-12.7) | 4.8 (3.9-6.0) | |
| Sex† | |||||
| Male | 12 072 | 76 | 11.4 (9.1-14.2) | 4.7 (3.5-6.3) | .750 |
| Female | 9 623 | 55 | 10.0 (7.7-13.0) | 5.0 (3.6-7.1) | |
| Age at diagnosis† | |||||
| <70 y | 10 770 | 81 | 10.1 (8.2-12.6) | 7.8 (5.6-10.7) | <.001 |
| ≥70 y | 10 925 | 50 | 11.9 (9.0-15.6) | 3.1 (2.3-4.3) | |
| Period of diagnosis† | |||||
| 2000-2004 | 6 600 | 51 | 10.8 (8.2-14.2) | 6.0 (4.2-8.6) | .321 |
| 2005-2009 | 7 313 | 45 | 10.2 (7.6-13.7) | 4.5 (3.1-6.5) | |
| 2010-2014 | 7 782 | 35 | 11.4 (8.2-15.8) | 4.0 (2.6-6.1) | |
| Lymphoma group† | |||||
| Low-grade NHL | 10 091 | 57 | 8.8 (6.8-11.3) | 4.1 (3.0-5.7) | .355 |
| High-grade NHL | 11 088 | 70 | 12.8 (10.1-16.2) | 5.6 (4.2-7.6) | |
| Other/unknown | 516 | 4 | 17.7 (6.6-47.1) | 6.2 (1.7-21.8) | |
| Lymphoma subtype† | |||||
| Diffuse large B cell | 8 144 | 46 | 11.0 (8.3-14.7) | 5.1 (3.5-7.5) | .657 |
| Follicular | 3 593 | 27 | 10.2 (7.0-14.8) | 5.4 (3.2-9.0) | |
| Mantel cell | 1 360 | 9 | 15.1 (7.9-29.1) | 4.9 (2.2-10.9) | |
| Marginal zone | 1 298 | 6 | 7.0 (3.2-15.6) | 3.0 (1.1-8.0) | |
| Burkitt | 227 | 2 | 15.0 (3.8-60.2) | 3.2 (0.6-16.5) | |
| T cell | 1 648 | 13 | 17.0 (9.9-29.2) | 8.5 (4.0-18.2) | |
| Other | 5 425 | 28 | 9.3 (6.4-13.4) | 4.1 (2.6-6.4) | |